Peptides for Dermatology

2 research peptides are currently studied for dermatology. This guide ranks them by evidence strength and covers their mechanisms, safety profiles, and current clinical status.

Afamelanotide is a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH), consisting of 13 amino acids and possessing a molecular weight of approximately 1646.9 g/mol. This peptide has garnered FDA approval for the treatment of erythropoietic protoporphyria (EPP), a genetic disorder that leads to painful skin reactions upon sun exposure. Clinical studies have demonstrated that afamelanotide significantly increases pain-free time in sunlight for patients suffering from EPP, suggesting its role in enhancing skin tolerance to UV radiation. Additionally, it stimulates the production of eumelanin, contributing to skin darkening and potentially offering a protective effect against UV damage. The approved status reflects robust evidence from clinical trials, although further research may be needed to fully elucidate its long-term safety and efficacy in broader dermatological applications.

Omiganan (MBI 226) is a 12-amino-acid synthetic cationic antimicrobial peptide, with a molecular weight of approximately 1779 g/mol, derived from the natural antimicrobial peptide indolicidin found in bovine neutrophils. While it has been investigated in Phase III clinical trials for its potential to prevent catheter-related infections and as a topical treatment for papulopustular rosacea (marketed as CLS001), it has yet to receive regulatory approval for these indications. The evidence supporting omiganan's efficacy includes studies indicating its ability to reduce catheter colonization, thereby potentially lowering the risk of infections. In dermatological research, its application for treating rosacea has shown promise, but the absence of regulatory approval highlights the need for further validation of its safety and effectiveness in these contexts. Limitations in the available data, such as sample sizes and trial designs, warrant cautious interpretation of its potential benefits.